Tomoaki Shirakawa
- kawaokashinpei3
- Jul 7
- 2 min read
Selected journal : Science
Mitochondrial metabolism and signaling direct dendritic cell function in antitumor immunity
What is the main question of the paper?
How do intratumoral cDC1s maintain their antigen-presenting and CD8 T cell–activating function, and why is this function lost during tumor progression?
How did the anthor address the question?
■Step1
They identified functionally distinct mitochondrial states in intratumoral cDC1s.
The authors first showed that intratumoral cDC1s can be divided into mitochondrial-high and mitochondrial-low states based on mitochondrial membrane potential relative to mitochondrial mass. cDC1s with polarized mitochondria showed higher OXPHOS activity, better mitochondrial structure, higher MHC-I/MHC-II expression, and stronger ability to activate CD8 T cells. This suggested that the immunogenic function of cDC1s is linked to their mitochondrial fitness.
■Step2
They demonstrated that the OPA1–NRF1–OXPHOS axis supports cDC1 antigen presentation.
Mechanistically, OPA1 maintained NRF1 activity and electron transport chain function, thereby supporting mitochondrial respiration, ATP production, and NAD+/NADH balance. When OPA1 or NRF1 was impaired, cDC1s showed reduced OXPHOS and enhanced autophagy/lysosome activity, leading to increased degradation of MHC-I and antigen. As a result, antigen presentation and CD8 T cell activation were impaired.
■Step3
They connected this mechanism to tumor progression and therapeutic response.
During tumor progression, intratumoral cDC1s progressively lost mitochondrial membrane potential, mitochondrial volume, and OPA1–NRF1 signaling. Conversely, intratumoral administration of mitochondrially fit cDC1s suppressed tumor growth, and the effect was further enhanced when combined with immune checkpoint blockade.
What is the “strength” of the paper?
The strength of this study is that it explains cDC1 dysfunction in tumors from the perspective of mitochondrial function, rather than simply describing it as suppression by the tumor microenvironment. By linking mitochondrial function to antigen presentation, CD8 T cell responses, and the effect of immune checkpoint blockade, the authors present a clear mechanistic story of how cDC1 function is lost and can be restored.
Comment
By cross-referencing their dataset with public databases, the authors have confirmed that the two cDC1 subpopulations of interest (TMRM/MGhi and TMRM/MGlo) can be identified in multiple mouse models and human samples. I think this is an important step toward clinical application.
Comment by Yuki Nakamura
